HER2 overexpression is driven by amplification of the ERBB2 gene located at the long arm of human chromosome 17 (17q12) The humanised monoclonal antibody trastuzumab is a component of standard of care for multiple different treatment regimens in HER2-positive breast cancer [3–7]. Here, ERBB2 is linked to breast cancer.